Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura.
Fiche publication
Date publication
novembre 2019
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul, Dr OJEDA-URIBE Mario
Tous les auteurs :
Garraud O, Malot S, Herbrecht R, Ojeda-Uribe M, Lin JS, Veyradier A, Payrat JM, Liu K, Corash L, Coppo P
Lien Pubmed
Résumé
Therapeutic Plasma Exchange (TPE) is the primary therapy of immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP). Efficacy and safety data for TPE of iTTP have been assessed with Quarantine and Solvent-Detergent inactivated (SD) plasma. Here, amotosalen-UVA pathogen inactivated (AI) plasma, also in routine use, was evaluated in iTTP.
Mots clés
ADAMTS13, Plasma, Plasma exchange, Rituximab, Thrombotic thrombocytopenic purpura
Référence
Transfus. Apher. Sci.. 2019 Nov 5;:102665